Elacytarabine: Antimetabolite, oncolytic

Drugs of the Future

Volumn 34, Issue 12, 2009, Pages 941-949

  Burke, A ^a   Swords, R ^a   Kelly, K ^a   Giles, F J ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETABOLITE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; CLORETAZINE; CP 4055; CYTARABINE; DOCETAXEL; ELACYTARABINE; GEMCITABINE; IDARUBICIN; IRINOTECAN; OXALIPLATIN; P 4055; SORAFENIB; TOPOTECAN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CLINICAL STUDY; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; FATIGUE; FEBRILE NEUTROPENIA; FEVER; HAND FOOT SYNDROME; HEADACHE; HEMATOLOGIC MALIGNANCY; HUMAN; IC 50; KLEBSIELLA INFECTION; LEUKOPENIA; LIVER DYSFUNCTION; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MAXIMUM TOLERATED DOSE; MELANOMA; NAUSEA; NEUTROPENIA; NONHUMAN; OVARY CANCER; RECOMMENDED DRUG DOSE; SIDE EFFECT; THROMBOCYTOPENIA; TUMOR LYSIS SYNDROME; TYPHILITIS; VOMITING;

EID: 84930536852     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2009.034.12.1424269     Document Type: Article

References (60)

1. Myhren, F., Dalen, A., Stokke, K.T., Borretzen, B. (Norsk Hydro AS). Improved therapeutic agents. JP 2002504068, JP 2009215326, US 6316425, US 6335322, WO 1997005154.
2. Blum, W., Marcucci, G. New approaches in acute myeloid leukemia. Best Pract Res Clin Haematol 2008, 21(1): 29-41.
3. Dillman, R.O., Davis, R.B., Green, M.R. et al. A comparative study of two different doses of cytarabine for acute myeloid leukemia: A phase III trial of Cancer and Leukemia Group B. Blood 1991, 78(10): 2520-2526
4. Weick, J.K., Kopecky, K.J., Appelbaum, F.R. et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group study. Blood 1996, 88(8): 2841-2851
5. Frick, J.C., Hansen, R.M., Anderson, T., Ritch, P.S. Successful high-dose intravenous cytarabine treatment of parenchymal brain involvement from malignant lymphoma. Arch Intern Med 1986, 146(4): 791-792
6. Wheatley, K., Brookes, C.L., Howman, A.J. et al. Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. Br J Haematol 2009, 145(5): 598-605.
7. Furth, J.J., Cohen, S.S. Inhibition of mammalian DNA polymerase by the 5′-triphosphate of 1-beta-d-arabinofuranosylcytosine and the 5′-triphosphate of 9-beta-d-arabinofuranoxyladenine. Cancer Res 1968, 28(10): 2061-2067
8. Ross, D.D., Chen, S.R., Cuddy, D.P. Effects of 1-beta-D- arabinofuranosylcytosine on DNA replication intermediates monitored by pH-step alkaline elution. Cancer Res 1990, 50(9): 2658-2666
9. Wiley, J.S., Jones, S.P., Sawyer, W.H. Cytosine arabinoside transport by human leukaemic cells. Eur J Cancer Clin Oncol 1983, 19(8): 1067-1074
10. Baldwin, S.A., Beal, P.R., Yao, S.Y., King, A.E., Cass, C.E., Young, J.D. The equilibrative nucleoside transporter family, SLC29. Pflugers Arch 2004, 447(5): 735-743
11. Baldwin, S.A., Yao, S.Y., Hyde, R.J. et al. Functional characterization of novel human and mouse equilibrative nucleoside transporters (hENT3 and mENT3) located in intracellular membranes. J Biol Chem 2005, 280(16): 15880-15887
12. Clarke, M.L, Damaraju, V.L., Zhang, J. et al. The role of human nucleoside transporters in cellular uptake of 4′-thio-beta-D- arabinofuranosylcytosine and beta-D-arabinosylcytosine. Mol Pharmacol 2006, 70(1): 303-310 (Pubitemid 43920820)
13. Chou, T.C., Arlin, Z., Clarkson, B.D., Phillips, F.S. Metabolism of 1-beta-D-arabinofuranosylcytosine in human leukemic cells. Cancer Res 1977, 37(10): 3561-3570
14. Schrecker, A.W., Goldin, A. Antitumor effect and mode of action of 1-beta-D-arabinofuranosylcytosine 5′-phosphate in leukemia L1210. Cancer Res 1968, 28(4): 802-803
15. Chottiner, E.G., Shewach, D.S., Datta, N.S. et al. Cloning and expression of human deoxycytidine kinase cDNA. Proc Natl Acad Sci U S A 1991, 88(4): 1531-1535
16. Galmarini, C.M., Jordheim, L., Dumontet, C. Role of IMP-selective 5′-nucleotidase (cN-II) in hematological malignancies. Leuk Lymphoma 2003, 44(7): 1105-1111 (Pubitemid 36609103)
17. Yamauchi, T., Negoro, E., Kishi, S. et al. Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5′-nucleotidase II expression ratio in primary acute myeloid leukemia cells. Biochem Pharmacol 2009, 77(12): 1780-1786
18. Ho, D.H., Frei, E. 3rd. Clinical pharmacology of 1-beta-d- arabinofuranosyl cytosine. Clin Pharmacol Ther 1971, 12(6): 944-954
19. Ho, D.H. Distribution of kinase and deaminase of 1-beta-D- arabinofuranosylcytosine in tissues of man and mouse. Cancer Res 1973, 33(11): 2816-20.
20. Kufe, D., Spriggs, D., Egan, E.M., Munroe, D. Relationships among ara-CTP pools, formation of (ara-C) DNA, and cytotoxicity of human leukemic cells. Blood 1984, 64(1): 54-58
21. Galmarini, C.M., Thomas, X., Calvo, F. et al. In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia. Br J Haematol 2002, 117(4): 860-868
22. Hubeek, I., Stam, R.W., Peters, G.J. et al. The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia. Br J Cancer 2005, 93(12): 1388-1394 (Pubitemid 41752866)
23. Veuger, M.J., Honders, M.W., Landegent, J.E., Willemze, R., Barge, R.M. High incidence of alternatively spliced forms of deoxycytidine kinase in patients with resistant acute myeloid leukemia. Blood 2000, 96(4): 1517-24.
24. Flasshove, M., Strumberg, D., Ayscue, L. et al. Structural analysis of the deoxycytidine kinase gene in patients with acute myeloid leukemia and resistance to cytosine arabinoside. Leukemia 1994, 8(5): 780-785 (Pubitemid 24161082)
25. Lamba, J.K., Crews, K., Pounds, S. et al. Pharmacogenetics of deoxycytidine kinase: Identification and characterization of novel genetic variants. J Pharmacol Exp Ther 2007, 323(3): 935-945 (Pubitemid 350146062)
26. Galmarini, C.M., Graham, K., Thomas, X. et al. Expression of high Km 5′-nudeotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukemia. Blood 2001, 98(6): 1922-1926
27. Galmarini, C.M., Thomas, X., Graham, K. et al. Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabine. Br J Haematol 2003, 122(1): 53-60. (Pubitemid 36819338)
28. Gati, W.P., Paterson, A.R., Belch, A.R., Chlumecky, V., Larratt, L.M., Mant, M.J., Turner, A.R. Es nucleoside transporter content of acute leukemia cells: Role in cell sensitivity to cytarabine (araC). Leuk Lymphoma 1998, 32(1-2): 45-54. (Pubitemid 29086382)
29. Gati, W.P., Paterson, A.R., Larratt, L.M., Turner, A.R., Belch, A.R. Sensitivity of acute leukemia cells to cytarabine is a correlate of cellular es nucleoside transporter site content measured by flow cytometry with SAENTA-fluorescein. Blood 1997, 90(1): 346-353
30. Wiley, J.S., Jones, S.P., Sawyer, W.H., Paterson, A.R. Cytosine arabinoside influx and nucleoside transport sites in acute leukemia. J Clin Invest 1982, 69(2): 479-489
31. Galmarini, C.M., Thomas, X., Calvo, F., Rousselot, P., El Jafaari, A., Cros, E., Dumontet, C. Potential mechanisms of resistance to cytarabine in AML patients. Leuk Res 2002, 26(7): 621-629 (Pubitemid 34465699)
32. Wiley, J.S., Taupin, J., Jamieson, G.P., Snook, M., Sawyer, W.H., Finch, L.R. Cytosine arabinoside transport and metabolism in acute leukemias and T cell lymphoblastic lymphoma. J Clin Invest 1985, 75(2): 632-642
33. Bhalla, K., Nayak, R., Grant, S. Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D- arabinofuranosylcytosine. Cancer Res 1984, 44(11): 5029-5037
34. Dumontet, C., Fabianowska-Majewska, K., Mantincic, D. et al. Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562. Br J Haematol 1999, 106(1): 78-85. (Pubitemid 29343530)
35. Hapke, D.M., Stegmann, A.P., Mitchell, B.S. Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity. Cancer Res 1996, 56(10): 2343-2347
36. Owens, J.K., Shewach, D.S., Ullman, B., Mitchell, B.S. Resistance to 1-beta-D-arabinofuranosylcytosine in human T-lymphoblasts mediated by mutations within the deoxycytidine kinase gene. Cancer Res 1992, 52(9): 2389-2393
37. van den Heuvel-Eibrink, M.M., Wiemer, E.A., Kuijpers, M., Pieters, R., Sonneveld, P. Absence of mutations in the deoxycytidine kinase (dCK) gene in patients with relapsed and/or refractory acute myeloid leukemia (AML). Leukemia 2001, 15(5): 855-856
38. Neff, T., Blau, C.A. Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine. Exp Hematol 1996, 24(11): 1340-1346 (Pubitemid 26348932)
39. Harris, A.L., Grahame-Smith, D.G., Potter, C.G., Bunch, C. Cytosine arabinoside deamination in human leukaemic myeloblasts and resistance to cytosine arabinoside therapy. Clin Sci (Lond) 1981, 60(2): 191-198
40. Kreis, W., Woodcock, T.M., Gordon, C.S., Krakoff, I.H. Tetrahydrouridine: Physiologic disposition and effect upon deamination of cytosine arabinoside in man. Cancer Treat Rep 1977, 61(7): 1347-1353
41. Bergman, A.M., Kuiper, C.M., Voorn, D.A. et al. Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines. Biochem Pharmacol 2004, 67(3): 503-511 (Pubitemid 38232890)
42. Tanaka, M., Yoshida, S. Altered sensitivity to 1-beta-D- arablnofuranosylcytosine 5′-triphosphate of DNA polymerase alpha from leukemic blasts of acute lymphoblastic leukemia. Cancer Res 1982, 42(2): 649-653
43. Clavis Pharma ASA Web site. [cited; Available from: http://www. clavispharma.com/Technology].
44. Kuiper, C.M. et al. Lipophilic 1-ß-D-arabinofuranosyl cytosine (ara-C) derivatives: Cell specific cytotoxicity and structure-activity relationship (SAR). Proc Am Assoc Cancer Res 1998, 39.
45. Adema, A., Smid, K., Losekoot, N., Myhren, F., Sandvold, M.L., Peters, G.J. Fatty acid derivatives of cytarabine and gemcitabine, CP-4055 and CP-4126, show a prolonged cellular retention compared to the parent drug. Proc Am Assoc Cancer Res (AACR) 2008, 49: Abst 5740.
46. Breistol, K., Balzarini, J., Sandvold, M.L., Myhren, F., Martinsen, M., De Clercq, E., Fodstad, O. Antitumor activity of P-4055 (elaidic acid-cytarabine) compared to cytarabine in metastatic and s.c. human tumor xenograft models. Cancer Res 1999, 59(12): 2944-2949 (Pubitemid 29283136)
47. Galmarini, C.M., Myhren, F., Sandvold, M.L. CP-4055 and CP-4126 are active in ara-C and gemcitabine-resistant lymphoma cell lines. Br J Haematol 2009, 144(2): 273-275
48. Bruheim, S., Milandsmo, G., Sandvold, M.L., Myhren, F., Fodstad, O. Antitumor activity of CP-4055 is enhanced in combination with bevacizumab, cetuximab, and trastuzumab in human NSCLC xenografts. AACR-NCI-EORTC lnt Conf Mol Targets Cancer Ther (Oct 22-26, San Francisco) 2007, Abst B287.
49. Adema, A.D., Bergman, A.M., Myhren, F., Sandvold, M.L., Fichtner, I., Peters, G.J. The fatty acid derivatives of ara-C, CP-4055, and gemcitabine, CP-4126, enhance the cytotoxic effect of oxaliplatin and docetaxel. Proc Am Assoc Cancer Res (AACR) 2006, 47: Abst 2119.
50. Adams, D.J., Sandvold, M.L., Myhren, F., Jacobsen, T.F., Giles, F., Rizzieri, D.A. Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells. Leuk Lymphoma 2008, 49(4): 786-797
51. Raymond, E. et al. Pharmacokinetics of a nucleoside analogue CP-4055 in two phase I trials using a daily for 5 days schedule and three intermittent weekly or biweekly schedules. Proc Am Assoc Cancer Res (AACR) 2005, 46: Abst 3975.
52. Dueland, S., Aamdal, S., Lind, M.J., Thomas, H., Sandvold, M.L., Gaullier, J.M., Rasch, W. Intravenous administration of CP-4055 (ELACYT) in patients with solid tumours. A phase I study. Acta Oncol 2009, 48(1): 137-45.
53. Delaunoit, T. et al. A three schedule phase I trial of CP-4055, weekly and q2 weeks in patients with advanced or metastatic solid tumors. 42nd Annu Meet Am Soc Clin Oncol (ASCO) (June 3-6, Atlanta) 2006, Abst 2067.
54. Aamdal, S., Dueland, S., Lind, M.J., Thomas, H., Franks, C., Sandvold, M.L., Rasch, W. Favorable phase I clinical results and pharmacokinetic (PK) data with the novel lipid vector technology-cytotoxic agent, CP-4055. Proc Am Assoc Cancer Res (AACR) 2005, 46: Abst 3976.
55. O'Brien, S., Rizzieri, D.A., Vey, N. et al. A phase I/II study with CP-4055 in patients with haematologic malignancies. Blood [50th Annu Meet Am Soc Hematol (Dec 6-9, San Francisco) 2008] 2008, 112(11): Abst 949.
56. Giles, F., O'Brien, S.M., Vey, N. et al. A phase I study with CP-4055 in patients with haematologic malignancies. Haematologica [13th Congr Eur Hematol Assoc (EHA) (June 12-15, Copenhagen) 2008] 2008, 93(Suppl. 1): Abst 0036.
57. Aamdal, S., Dueland, S., Lind, M.J., Thomas, H., Franks, C.R., Sandvold, M.L., Rasch, W. Phase I trial of a nucleoside analog CP-4055 given daily for 5 days every 3 weeks in patients (pts) with advanced solid tumors - Preliminary results. 40th Annu Meet Am Soc Clin Oncol (ASCO) (June 5-8, New Orleans) 2004, Abst 2049.
58. Raymond, E. et al. Phase I trial of CP-4055, a novel cytotoxic agent, given according to three intermittent weekly or biweekly schedules in patients with advanced or metastatic solid tumors: Preliminary results. Proc Am Assoc Cancer Res (AACR) 2005, 46: Abst 473.
59. O'Brien, S., Rizzieri, D., Padmanabhan, S. et al. A phase I study with CP-4055 and idarubicin in patients with refractory/relapsed AML 14th Congr Eur Hematol Assoc (EHA) (June 4-7, Berlin) 2009, Abst 0310.
60. O'Brien, S., Rizzieri, D., Vey, N. et al. A phase II study with CP-4055 as second salvage therapy in patients with AML. 14th Cong Eur Hematol Assoc (EHA) (June 4-7, Berlin) 2009, Abst 1394.